References
1. Du L., Ha C. Epidemiology and Pathogenesis of Ulcerative Colitis. Gastroenterol. Clin. North Amer. 2020; 49 (4): 643–54. DOI: https://doi.org/10.1016/j.gtc.2020.07.005
2. Ordás I., Eckmann L., Talamini M., Baumgart D.C., Sandborn W.J. Ulcerative colitis. Lancet. 2012; 380 (9853): 1606–19. DOI: https://doi.org/10.1016/S0140-6736(12)60150-0
3. Chulkina M.M., Pichugin A.V., Ataullaukhanov R.I. Therapeutic effect of the immunomodulating peptide TEKKRRETVEREKE in the experimental model of induced ulcerative colitis in mice. Immunologiya. 2019; 40 (1): 15–26. DOI: https://doi.org/10.24411/0206-4952-2019-11002 (in Russian)
4. Rawat M., Nighot M., Al-Sadi R., Gupta Y., Viszwapriya D., Yochum G., Koltun W., Ma T.Y. IL1β increases intestinal tight junction permeability by upregulation of MIR200C-3p, which degrades occluding mRNA. Gastroenterol. 2020; 159 (4): 1375–89. DOI: https://doi.org/10.1053/j.gastro.2020.06.038
5. Jialing L., Yangyang G., Jing Z., Xiaoyi T., Ping W., Liwei S., Simin C. Changes in serum inflammatory cytokine levels and intestinal flora in a selfhealing dextran sodium sulfate-induced ulcerative colitis murine model. Life Sci. 2020; 263: 118587. DOI: https://doi.org/10.1016/j.lfs.2020.118587
6. Goulart R. de A., Barbalho S.M., Lima V.M., Souza G.A., Mathias J.N., Araujo A.C., Rubira C.J., Buchaim R.L., Buchaim D.V., de Carvalho A.C.A., Guiger E.L. Effects of the use of Curcumin on ulcerative colitis and Crohn’n disease. J. Med. Food. 2020; 24 (7): 675–85. DOI: https://doi.org/10.1089/jmf.2020.0129
7. Tatiya-Aphiradee N., Chatuphonprasert W., Jarukamjorn K. Immune response and inflammatory pathway of ulcerative colitis. J. Bas. Clin. Physiol. Pharmacol. 2018; 30 (1): 1–10. DOI: https://doi.org/10.1515/jbcpp-2018-0036
8. Schoultz I., Keita A.V. Cellular and molecular therapeutic targets in inflammatory bowel disease-focusing on intestinal barrier function. Cells. 2019; 8 (2): 193–216. DOI: https://doi.org/10.3390/cells8020193
9. Iwakura Y., Ishigame H., Saijo S., Nakae S. Functional specialization of interleukin17 family members. Immunity. 2011; 34 (2): 149–62. DOI: https://doi.org/10.1016/j.immuni.2011.02.012
10. Lin H., Zhang W., Jiang X., Chen R., Huang X., Huang Z. Total glucosides of paeony ameliorates TNBS-induced colitis by modulating differentiation of Th17/Treg cells and the secretion of cytokines. Mol. Med. Rep. 2017; 16 (6): 8265–76. DOI: https://doi/org/ https://doi.org/10.3892/mmr.2017.7598
11. Nishida Y., Hosomi S., Watanabe K., Watanabe K., Yukawa T., Otani K., Nagami Y., Tanaka F., Taira K., Kamata N., Yamagami H., Tanigawa T., Watanabe T., Fujiwara Y. Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis. Scand. J. Gastroenterol. 2018; 53 (5): 579–85. DOI: https://doi.org/10.1080/00365521.2017.1403647
12. Wang G., Liu Y., Yang Y., Xia Y., Lai P.F.-H., Ai L. The ameliorative effect of a Lactobacillus strain with good adhesion ability against dextran sulfate sodium-induced murine colitis. Food & Func. 2019; 10 (1): 397–409. DOI: https://doi.org/10.1039/c8fo01453a
13. Saez-Lara M.J., Gomez-Llorente -C., Plaza-Diaz J., Gil H. The role of probiotic lactic bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed. Res. Int. 2015; 505878. DOI: https://doi.org/10.1155/2015/505878
14. Seo S., Shin J.-S., Lee W.-S., Rhee J.K., Cho C-W., Hong H.D., Lee K.T. Anti-colitis effect of Lactobaccilus sakei K040706 via suppression of inflammatory responses in dextran sulfate sodium-induced colitis mice model. J. Func. Foods. 2017; 29: 256–68. DOI: https://doi.org/10.1016/j.jff.2016.12.045
15. Braat H., Peppelenbosch M.P., Hommes D.W. Interleukin-10-based therapy for inflammatory bowel disease. Exp. Opin. Biol. Ther. 2003; 3 (5): 725–31. DOI: https://doi.org/10.1517/14712598.3.5.725
16. Katsannos K.H., Papadakis K.A. Inflammation bowel disease: Updates on Molecular targets for biologics. Gut Liver. 2017; 11 (4): 455–63. DOI: https://doi.org/10.5009/gn116308
17. Zhou X., Li W., Wang S., Zhang P., Wang O., Xiao J., Zang C., Zhang X., Xu X., Xue S., Hui L., Ji H., Wei B., Wang H. YAP Aggravates Inflammatory Bowel Disease by Regulating M1/M2 Macrophage Polarization and Gut Microbial Homeostasis. Cell Rep. 2019; 27 (4): 1176–89. DOI: https://doi.org/10.1016/j.celrep.2019.03.028
18. Zolotova N.A., Diatroptov M.E., Chernysheva M.B., Khochansky D.N., Kirukhin S.O., Postovalova E.A. Cytokines in colon of C57Bl/6 male mice with acute and chronic dextran-induced colitis. Tsitok. Vospal. 2015; 14 (2): 70–6. (in Russian)
19. Bulgakov S.A. Peptide therapeutics in pancreatology. Rus. J. Evid.-bas. Gastroenterol. 2018; 7 (4): 30–4. DOI: https://doi.org/10.17116/dokgastro2018704130 (in Russian)
20. Platonova V.V., Sevbitov A.V., Shakaryants A.A., Dorofeev A.E. The experimental clinical substantiation of treatment of patients with odontogenic phlegmon of maxillofacial area using Dаlargin in complex therapy. Klin. Lab. Diagn. 2018; 63 (5): 293–6. DOI: https://doi.org/10.18821/0869-2084-2018-63-5-293-296 (in Russian)
21. Khomyakova T.I., Zolotova N.A., Khochanskiy D.N., Khomyakov Yu.N. The modelling of acute and chronic colitis in mice. Lechen. Profil. 2013; 7 (3): 148–59. (in Russian)
22. Lishmanov Yu.B., Maslov L.N., Naryzhnaya N.V., Pei J.-M., Kolar F., Zhang Y., Portnichenko A.G., Wang H. Endogenous opioid system as a mediator of acute and long-term adaptation to stress. Prospects for clinical use of opioid peptides. Annals RAMS. 2012; 6: 73–82. (in Russian)
23. Lipatov V.A., Kryukov A.A., Severinov D.A., Saakyan A.R. Ethical and legal aspects of in vivo experimental biomedical research. Part I. I.P. Pavlov Rus. Med. Biol. Herald. 2019; 27 (1): 80–92. DOI: https://doi.org/10.23888/PAVLOVJ201927180-92 (in Russian)
24. Lipatov V.A., Kryukov A.A., Severinov D.A., Saakyan A.R. Ethical and legal aspects of in vivo experimental biomedical research of the conduct. Part II. I.P. Pavlov Rus. Med. Biol. Herald. 2019; 27 (2): 245–57. DOI: https://doi.org/10.23888/PAVLOVJ2019272245-257 (in Russian)
25. Gao Y., Postovalova E.A., Dobrynina M.T., Makarova O.V. Sex differences of subpopulation composition of lymphocytes in the peripheral blood, mesenteric lymph nodes and colon in experimental chronic ulcerative colitis. Immunologiya. 2018; 39 (1): 32–8. DOI: https://doi.org/10.18821/0206- 4952-2018-39-1-32-38 (in Russian)
26. Phillippe D., Chakass D., Thuru X., Zerbib P., Tsicopoulos A., Geboes K., Bulois P., Vorng H., Gay J., Colombel J.-F., Desreumaux P., Chamaillard M. Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut. 2006; 55: 815–23. DOI: https://doi.org/10.1136/gut.2005.080887
27. Anselmi L., Huynh J., Duraffourd C., Jaramillo I., Vegezzi G., Saccani F., Boschetti E., Brecha N.C., De Giorgio R., Sternini C. Activation of μ opioid receptors modulates inflammation in acute experimental colitis. Neurogastroenterol. Motil. 2015; 27 (4): 509–23. DOI: https://doi.org/10.1111/nmo.12521
28. Basso L., Gamier L., Bessac A., Boue J., Blanpied C., Ctnac N., Laffont S., Dietrich G. T-lymphocyte-derived enkephalins reduce Th1/Th17 colitis and associated pain in mice. J. Gastroenterol. 2018; 53 (2): 215–26. DOI: https://doi.org/10.1007/s00535-017-1341-2
29. Sternini C., Patierno S., Selmer I.S., Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol. Motil. 2004; 458: 404–11.
30. Valdez-Morales E., Guerrero-Alba r., Ochoa-Cortes F., Benson J., Spreadbury I., Hurlbut D., Miranda-Morales M., Lomax A.E., Vanner S. Release of endogenous opioids during a chronic IBD model suppresses the excitability of colonic DRG neurons. Neurogastroenterol. Motil. 2013. 25 (1): 39–46. DOI: https://doi.org/10.1111/nmo.12008
31. Owczarek D., Cibor D., Mach T., Ciesla A., Pierzchala-Koziec K., Salapa K., Kusnierz-Cabala B. Met-enkephalins in patients with inflammatory bowel diseases. Adv. Med. Sci. 2011; 56 (2): 158–64. DOI: https://doi.org/10.2478/v10039-011-0051-x
32. Philippe D., Dubuquoy H., Groux H., Brun V., Choui-Mariot M.T.V., Gaveriaux-Ruff C., Colombel J.-F., Kieffer B.I., Desreumaux P. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J. Clin. Invest. 2003; 111 (9): 1329–38. DOI: https://doi.org/10.1172/JCI16750
33. Di Cello J.J., Saito A., Rajasekhar P., Eriksson E.M., McQuade R.M., Nowel C.J., Sebastian B.W., Fichna J., Veldhuis N.A., Canals M., Bunnet N.W., Carbone S.E., Poole D.P. Inflammation-associated changes in DOR expression and function in the mouse colon. Am. J. Physiol. Gastrointest. Liver Physiol. 2018; 315 (4): G544–59. DOI: https://doi.org/10.1152/ajpgi.00025.2018
34. Shouval D.S., Ouahed J., Biswiss A., Goettel J.A., Horwitz B.H., Klein C., Muise A.M., Snapper S.B. Interleukin 10 receptor signaling: master regulatot of intestinal mucosal homeostasis in mice and humans. Adv. Immunol. 2014; 122: 177–210. DOI: https://doi.org/10.1016/B978-0-12-800267-4.00005-5
35. Neuman C., Scheffold A., Rutz S. Functions and regulation of T cell-derived interleukin-10. Sem. Immun. 2019; 44: 101344. DOI: https://doi.org/10.1016/j.smim.2019.101344
36. Wang S., Wang J., Ma R., Yang S., Fan T., Cao J., Wang Y., Ma W., Yang W., Wang F., Zang H. IL-10 enhances T cell survival and is associated with faster relapse in patients with inactive ulcerative colitis. Mol. Immunol. 2020; 121: 92–8. DOI: https://doi.org/10.1016/j.molimm.2020.03.001
37. Yoshimoto T. The hunt for the source of primary interleukin-4: how we discovered that natural killer T cells and basophils determine T helper type 2 cell differentiation in vivo. Front. Immunol. 2018; 9: 716. DOI: https://doi.org/10.3389/fimmu.2018.00716